MK-677

Origin and Structure

MK-677 — also called ibutamoren and developed under the code name L-163,191 — is not a peptide. It is a small-molecule spiropiperidine engineered by Merck in the mid-1990s as an orally bioavailable, long-acting agonist at the ghrelin receptor (GHSR-1a). The project was part of a broader effort to build "GH replacement in a pill" alternatives to recombinant human GH, sidestepping both the injection requirement and the supraphysiologic dosing problems associated with rhGH.

MK-677's inclusion in peptide libraries is a matter of mechanism, not chemistry: it acts at the same receptor as the classical GHRPs and is used in the same clinical and research contexts. Its oral bioavailability (roughly 60%) and long plasma half-life (approximately 24 hours) distinguish it sharply from every injectable compound in the class.

Mechanism of Action

MK-677 produces sustained activation of GHSR-1a in the pituitary and hypothalamus. Unlike the short-acting GHRPs, which produce discrete GH pulses and then clear, MK-677 produces round-the-clock elevation of GH pulse amplitude and frequency with a characteristic 24-hour IGF-1 elevation — typically 40-60% above baseline at daily doses of 25 mg in healthy adults. IGF-1 rather than GH is the more useful biomarker because of GH's short half-life and pulsatile kinetics.

The pharmacology is otherwise GHRP-like: modest cortisol and prolactin elevations, meaningful appetite stimulation driven by arcuate GHSR-1a activation, and preserved negative feedback through circulating IGF-1.

Clinical Evidence

MK-677 has one of the largest clinical evidence bases of any compound on this library that is nevertheless not approved. Published trials include:

• Healthy elderly adults. A 2008 Merck-sponsored trial in men and women aged 60-81 demonstrated roughly 20% increases in IGF-1 and modest body-composition improvements over 12 months at 25 mg daily.
• Hip fracture recovery. A multicenter trial in elderly patients post-hip fracture showed functional improvements on gait-speed measures.
• Frailty and muscle wasting. Several academic trials have examined MK-677 in sarcopenia and cachexia contexts.
• Pediatric GH deficiency. Phase 2 work in GHD children was completed but did not advance.

Merck's Alzheimer's program — which had explored MK-677 based on the hypothesis that IGF-1 elevation might affect cognitive decline — was halted in 2013 after failing to demonstrate efficacy. That failure, combined with concerns about insulin resistance and fluid retention observed across the trial program, ended Merck's pursuit of an approval.

Practical Considerations

Research-use dosing is typically 10-25 mg taken orally, once daily, most often at bedtime to align with endogenous overnight GH release. Food effects on absorption are minor. The 24-hour IGF-1 elevation is the dominant feature — users typically see measurable IGF-1 increases within a week and subjective sleep-quality and appetite changes within days. Cycling is common but not strictly necessary to maintain response, since the long half-life and sustained receptor activation do not produce the same rapid tachyphylaxis seen with hexarelin.

Safety and Regulatory Status

The two most consistent safety signals in MK-677 trials are worsening insulin sensitivity and fluid retention. Fasting glucose and HbA1c both increase modestly in most subjects, and a minority develop clinically meaningful hyperglycemia — a particular concern in patients with pre-existing insulin resistance or a diabetes family history. Water retention can produce rapid weight gain (several pounds in the first two weeks), mild edema, and occasional joint or muscle pain. Congestive heart failure was an exclusion criterion in multiple trials after early signals of problematic fluid handling in susceptible patients.

MK-677 is not FDA-approved. It has been on the WADA prohibited list since 2013 (class S2). It is widely available through research-chemical vendors, and — because it is an orally active small molecule rather than an injectable peptide — it is frequently mischaracterized as a "SARM" or lumped with performance-enhancement compounds in ways that obscure its pharmacology. For a broader category overview, see ipamorelin for the injectable counterpart profile and our recovery peptide guide.